Key result
Nanoparticle-delivered IRF5 siRNA suppresses inflammatory macrophages and attenuates post-MI heart failure development.
Why the study?
Persistence of inflammatory M1 macrophages may derail healing and compromise organ function, prompting evaluation of whether silencing the transcription factor IRF5 improves infarct healing and post-MI remodeling.
Does nanoparticle-delivered siRNA targeting IRF5 improve infarct healing and attenuate post-MI heart failure in mice models?
Does nanoparticle-delivered siRNA targeting IRF5 improve infarct healing and attenuate post-MI heart failure in mice models?
Answers are grounded in this paper and cite their sources.
In vivo silencing of IRF5 in macrophages promotes resolution of inflammation and improves healing after myocardial infarction in mice, suggesting a novel therapeutic target for post-MI remodeling.
Objectives The aim of the study was to test wether silencing of the transcription factor Interferon Regulatory Factor 5 (IRF5) in cardiac macrophages improves infarct healing and attenuates post-MI remodeling. Background In healing wounds, M1➛M2 macrophage phenotype transition supports resolution of inflammation and tissue repair. Persistence of inflammatory M1 macrophages may derail healing and compromise organ functions. The transcription factor IRF5 promotes genes associated with M1 macrophages. Methods Here we used nanoparticle-delivered siRNA to silence the transcription factor IRF5 in macrophages residing in myocardial infarcts (MI) and in surgically induced skin wounds in mice. Results Infarct macrophages expressed high levels of IRF5 during the early inflammatory wound healing stages (day 4 after coronary ligation) whereas expression of the transcription factor decreased during the resolution of inflammation (day 8). Following in vitro screening, we identified an siRNA sequence that, when delivered by nanoparticles to wound macrophages, efficiently suppressed expression of IRF5 in vivo. Reduction of IRF5 expression, a factor that regulates macrophage polarization, reduced inflammatory M1 macrophage markers, supported resolution of inflammation, accelerated cutaneous and infarct healing and attenuated development of post-MI heart failure after coronary ligation as measured by protease targeted FMT-CT imaging and cardiac MRI (p<0.05 respectively). Conclusion This work identifies a new therapeutic avenue to augment resolution of inflammation in healing infarcts by macrophage phenotype manipulation. This therapeutic concept may be used to attenuate post-MI remodeling and heart failure.
No takes yet. Share an insight, caveat, or question.
Courties et al. (2013) studied Myocardial infarction and skin wounds. Nanoparticle-delivered siRNA targeting IRF5 (siIRF5) vs. Control siRNA (siCON) was evaluated on Development of post-MI heart failure and infarct healing (measured by FMT-CT and cardiac MRI) (p=<0.05). Nanoparticle-delivered siRNA silencing of IRF5 reduced inflammatory M1 macrophage markers, accelerated healing, and attenuated post-MI heart failure development.
Synapse has enriched 10 related papers. Consider them for comparative context: